Alex Denner (Mark Neuling/CNBC/NBCU Photo Bank via Getty Images)
July 6, 2023 07:15 AM EDTUpdated 07:55 AM
People

Ex­clu­sive: Saris­sa's board push drew lit­tle sup­port in Alk­er­mes share­hold­er vote

Kyle LaHucik

Senior Reporter

Saris­sa Cap­i­tal Man­age­ment lost its proxy bat­tle bad­ly against Irish drug­mak­er Alk­er­mes last week, ac­cord­ing to a fi­nal tal­ly of votes for board nom­i­nees. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times